The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Open accessAbstract
We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway. In ovarian cancer (OC), DNMTis trigger cytosolic sensing of double-stranded RNA (dsRNA) causing a type I interferon response and apoptosis. Knocking down dsRNA sensors TLR3 and MAVS reduces this response 2-fold and blocking interferon beta or its receptor abrogates it. Upregulation of hypermethylated endogenous retrovirus (ERV) genes accompanies the response and ERV overexpression activates the response. Basal levels of ERV and viral defense gene expression significantly correlate in primary OC and the latter signature separates primary samples for multiple tumor types from The Cancer Genome Atlas into low versus high expression groups. In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The IFN-I response could also expose the tumor cells to surveillance by the immune system96, 97.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [97]
The cited source says what the claim attributes to it.
In the citing paper
“multiple studies have shown that DNA demethylating agents among other epigenetic modulators can induce a type I IFN response in cancer cells through the de-repression of endogenous retroviruses (ERVs) and activation of the MDA5-MAVS pathway38–40.”
From Epigenetic state determines the in vivo efficacy of STING agonist therapy (2023) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“DAC treatment could induce expression of retrotransposons normally silenced by DNA methylation, which could also augment tumor immunogenicity10–14,99.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“inactivated typical enhancers were associated with collagen fibril organization and chemotaxis GO terms and were enriched for binding motifs of immune-related TFs, including STAT1 (Fig. 2a, b)12,13.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“inhibiting EZH2 activity can either positively or negatively influence tumour-specific immune responses by modulating both tumour immunogenicity and the function of infiltrating T-cells, NK-cells and macrophages 196 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [196]
In the citing paper
“derepression of endogenous retroviral elements coupled to robust type I and type III IFN signaling”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chiappinelli et al., 2015
In the citing paper
“Certainly, this dual epigenetic targeting may influence additional antiproliferative mechanisms and further enhance antitumor surveillance by the immune system (Chiappinelli et al., 2015).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Chiappinelli et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,645
Flagged first, then by citations
1 of the 94 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 1,003
Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies
Iurescia, S., Fioretti, D. P., & Rinaldi, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00711 · Cited by 124
PRMT inhibition induces a viral mimicry response in triple-negative breast cancer
Wu, Q., Nie, D. Y., Ba-Alawi, W., Ji, Y., Zhang, Z., Cruickshank, J., Haight, J., Ciamponi, F. E., Chen, J., Duan, S., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01024-4 · Cited by 132
Espinet, E., Gu, Z., Imbusch, C. D., Giese, N. A., Büscher, M., Safavi, M., Weisenburger, S., Klein, C., Vogel, V., Falcone, M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1202 · Cited by 124
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 144
Activation of human endogenous retroviruses and its physiological consequences
Dopkins, N., & Nixon, D. F. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00674-z · Cited by 122
Immunogenic cell death in colon cancer prevention and therapy
Ruan, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23183 · Cited by 125
Blagitko‐Dorfs, N., Schlosser, P., Greve, G., Pfeifer, D., Meier, R., Baude, A., Brocks, D., Plass, C., & Lübbert, M. (2018) · Leukemia · doi:10.1038/s41375-018-0293-8 · Cited by 120
Emerging epigenetic-modulating therapies in lymphoma
Sermer, D. J., Pasqualucci, L., Wendel, H., Melnick, A. M., & Younes, A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0190-8 · Cited by 125
Targeting the immune microenvironment in acute myeloid leukemia: a focus on T cell immunity
Lamble, A. J., & Lind, E. F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00213 · Cited by 119
Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4
Mo, X., Zhang, H., Preston, S., Martin, K. A., Zhou, B., Vadalia, N., Gamero, A. M., Soboloff, J., Tempera, I., & Zaidi, M. R. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1615 · Cited by 125
Combination therapies with HSP90 inhibitors against colorectal cancer
Kryeziu, K., Bruun, J., Guren, T. K., Sveen, A., & Lothe, R. A. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.01.002 · Cited by 124
Diseases of the nERVous system: retrotransposon activity in neurodegenerative disease
Tam, O. H., Ostrow, L. W., & Hammell, M. (2019) · Mobile DNA · doi:10.1186/s13100-019-0176-1 · Cited by 127
Chun, H.-J. E., Johann, P. D., Milne, K., Zapatka, M., Büllesbach, A., Ishaque, N., Iskar, M., Erkek, S., Wei, L. L., Tessier‐Cloutier, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.013 · Cited by 117
Moufarrij, S., Srivastava, A., Gomez, S., Hadley, M. M., Palmer, E., Austin, P. T., Chisholm, S., Diab, N., Roche, K. C., Yu, A. Y. C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60409-4 · Cited by 119
Self-citationCobo, I., Tanaka, T. N., Mangalhara, K. C., Lana, A. J., Yeang, C., Han, C. Z., Schlachetzki, J. C. M., Challcombe, J., Fixsen, B. R., Sakai, M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.06.022 · Cited by 117
Induction of mouse totipotent stem cells by a defined chemical cocktail.
Hu, Y., Yang, Y., Tan, P., Zhang, Y., Han, M., Yu, J., Zhang, X., Jia, Z., Wang, D., Yao, K., et al. (2023) · Nature · doi:10.1038/s41586-022-04967-9 · Cited by 116
Deng, S., Hu, Q., Zhang, H., Yang, F., Peng, C., & Huang, C. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1068 · Cited by 116
Turning tumors from cold to inflamed to improve immunotherapy response
Gerard, C. L., Delyon, J., Wicky, A. M., Homicskó, K., Cuendet, M. A., & Michielin, O. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102227 · Cited by 118
Silencing of endogenous retroviruses by heterochromatin
Groh, S., & Schotta, G. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2454-8 · Cited by 114
Bao, X., Ren, T., Huang, Y., Sun, K., Wang, S., Liu, K., Zheng, B., & Guo, W. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.31 · Cited by 115
KAP1 regulates endogenous retroviruses in adult human cells and contributes to innate immune control
Tie, C. H. C., Fernandes, L., Conde, L., Robbez‐Masson, L., Sumner, R. P., Peacock, T., Rodriguez-Plata, M. T., Mickute, G., Gifford, R. J., Towers, G. J., et al. (2018) · EMBO Reports · doi:10.15252/embr.201745000 · Cited by 118
An overview of cancer health disparities: new approaches and insights and why they matter
Minas, T. Z., Bailey‐Whyte, M., Ajao, A., & Ambs, S. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa121 · Cited by 119
Shelkovnikova, T. A., Kukharsky, M. S., An, H., Dimasi, P., Alexeeva, S., Shabir, O., Heath, P. R., & Buchman, V. L. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0263-7 · Cited by 115
Complete loss of H3K9 methylation dissolves mouse heterochromatin organization
Montavon, T., Shukeir, N., Erikson, G. A., Engist, B., Onishi‐Seebacher, M., Ryan, D. P., Musa, Y., Mittler, G., Meyer, A. G., Genoud, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24532-8 · Cited by 115
The complementarity of DDR, nucleic acids and anti-tumour immunity
Kornepati, A. V. R., Rogers, C. M., Sung, P., & Curiel, T. J. (2023) · Nature · doi:10.1038/s41586-023-06069-6 · Cited by 117
FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells
Shen, J. Z., Qiu, Z., Wu, Q., Finlay, D., Garcia, G., Sun, D., Rantala, J., Barshop, W., Hope, J. L., Gimple, R. C., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.042 · Cited by 113
Effects of 5-Aza-2′-deoxycytidine (decitabine) on gene expression
Seelan, R. S., Mukhopadhyay, P., Pisano, M., & Greene, R. M. (2018) · Drug Metabolism Reviews · doi:10.1080/03602532.2018.1437446 · Cited by 118
Rautenberg, C., Germing, U., Haas, R. R., Kobbe, G., & Schroeder, T. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010228 · Cited by 113
Adoue, V., Binet, B., Malbec, A., Fourquet, J., Romagnoli, P., van Meerwijk, J. P. M., Amigorena, S., & Joffre, O. P. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.003 · Cited by 119
Transposable element regulation and expression in cancer
Grundy, E. E., Diab, N., & Chiappinelli, K. B. (2021) · FEBS Journal · doi:10.1111/febs.15722 · Cited by 125
Self-citationEpigenetic therapy in gastrointestinal cancer: the right combination
Abdelfatah, E., Kerner, Z. J., Nanda, N., & Ahuja, N. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16644247 · Cited by 115
HERVs New Role in Cancer: From Accused Perpetrators to Cheerful Protectors
Bannert, N., Hofmann, H., Block, A., & Höhn, O. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00178 · Cited by 112
Stimulation of Innate Immunity by Host and Viral RNAs
Streicher, F., & Jouvenet, N. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.10.009 · Cited by 111
The epigenomic landscape of transposable elements across normal human development and anatomy
Pehrsson, E. C., Choudhary, M. N. K., Sundaram, V., & Wang, T. (2019) · Nature Communications · doi:10.1038/s41467-019-13555-x · Cited by 111
The role of N6-methyladenosine mRNA in the tumor microenvironment
Li, M., Zha, X., & Wang, S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188522 · Cited by 114
Physiological functions of RIG-I-like receptors
Yoneyama, M., Kato, H., & Fujita, T. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.003 · Cited by 117
Chen, J., Harding, S. M., Natesan, R., Tian, L., Benci, J. L., Li, W., Minn, A. J., Asangani, I. A., & Greenberg, R. A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108080 · Cited by 111
5‐Fluorouracil efficacy requires anti‐tumor immunity triggered by cancer‐cell‐intrinsic STING
Tian, J., Zhang, D., Kurbatov, V., Wang, Q., Wang, Y., Fang, D., Wu, L., Bosenberg, M., Muzumdar, M. D., Khan, S. A., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020106065 · Cited by 114
Attig, J., Young, G. R., Hosie, L., Perkins, D., Encheva-Yokoya, V., Stoye, J. P., Snijders, A. P., Ternette, N., & Kassiotis, G. (2019) · Genome Research · doi:10.1101/gr.248922.119 · Cited by 113
Oncolytic Viruses: Exploiting Cancer's Deal with the Devil
Pikor, L. A., Bell, J. C., & Diallo, J. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.10.004 · Cited by 117
Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
Shi, T., Ma, Y., Yu, L., Jiang, J., Shen, S., Hou, Y., & Wang, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051389 · Cited by 112
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
Khawanky, N. E., Hughes, A., Yu, W., Myburgh, R., Matschulla, T., Taromi, S., Aumann, K., Clarson, J., Vinnakota, J. M., Shoumariyeh, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26683-0 · Cited by 108
The emerging role of immune checkpoint inhibition in malignant lymphoma
Hude, I., Sasse, S., Engert, A., & Bröckelmann, P. J. (2016) · Haematologica · doi:10.3324/haematol.2016.150656 · Cited by 109
Schmidt, N., Domingues, P., Gołębiowski, F., Patzina, C., Tatham, M. H., Hay, R. T., & Hale, B. G. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907031116 · Cited by 113
Leuzzi, G., Vasciaveo, A., Taglialatela, A., Chen, X., Firestone, T. M., Hickman, A. R., Mao, W., Thakar, T., Vaitsiankova, A., Huang, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.01.008 · Cited by 113
Fang, F., Cárdenas, H., Huang, H., Jiang, G., Perkins, S. M., Zhang, C., Keer, H. N., Liu, Y., Nephew, K. P., & Matei, D. E. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1492 · Cited by 110
Li, Z., Hua, X., Serra‐Cardona, A., Xu, X., Gan, S., Zhou, H., Yang, W., Chen, C.-L., Xu, R.-M., & Zhang, Z. (2020) · Science Advances · doi:10.1126/sciadv.abb5820 · Cited by 109
Clinical advances in targeting epigenetics for cancer therapy
Feng, S., & Carvalho, D. D. D. (2021) · FEBS Journal · doi:10.1111/febs.15750 · Cited by 109
Hu, J., Othmane, B., Yu, A., Li, H., Cai, Z., Chen, X., Ren, W., Chen, J., & Zu, X. (2021) · BMC Medicine · doi:10.1186/s12916-021-02163-6 · Cited by 109
Self-citationZhang, X. L., Zhang, R., & Yu, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00657 · Cited by 116
Signaling Through Nucleic Acid Sensors and Their Roles in Inflammatory Diseases
Okude, H., Ori, D., & Kawai, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.625833 · Cited by 104
Shadle, S. C., Zhong, J. W., Campbell, A. E., Conerly, M. L., Jagannathan, S., Wong, C.-J., Morello, T. D., van der Maarel, S. M., & Tapscott, S. J. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006658 · Cited by 102
Hasselbalch, H. C., & Holmström, M. O. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0700-2 · Cited by 106
Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer
Huang, K. C., Chiang, S., Chen, W. T., Chen, T.-W., Hu, C., Yang, P.-C., Ke, T., & Chao, K. S. C. (2020) · Cancers · doi:10.3390/cancers12020462 · Cited by 105
TET family dioxygenases and the TET activator vitamin C in immune responses and cancer
Yue, X., & Rao, A. (2020) · Blood · doi:10.1182/blood.2019004158 · Cited by 106
Epigenetic Regulation of Genomic Stability by Vitamin C
Brabson, J. P., Leesang, T. E., Mohammad, S., & Cimmino, L. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.675780 · Cited by 111
Travers, M., Brown, S. M., Dunworth, M., Holbert, C. E., Wiehagen, K. R., Bachman, K. E., Foley, J. R., Stone, M. L., Baylin, S. B., Casero, R. A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-4018 · Cited by 103
Self-citationSolovyov, A., Vabret, N., Arora, K. S., Snyder, A., Funt, S. A., Bajorin, D. F., Rosenberg, J. E., Bhardwaj, N., Ting, D. T., & Greenbaum, B. D. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.042 · Cited by 106
Self-citationSaleh, R., Toor, S. M., Nair, V. S., & Elkord, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01469 · Cited by 107
The role of aberrant DNA methylation in cancer initiation and clinical impacts
Geissler, F., Nesic, K., Kondrashova, O., Dobrovic, A., Swisher, E. M., Scott, C. L., & Wakefield, M. J. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231220511 · Cited by 112
Mendez‐Dorantes, C., & Burns, K. H. (2023) · Genes & Development · doi:10.1101/gad.351051.123 · Cited by 114
Role of Methylation in Pro- and Anti-Cancer Immunity
Mehdi, A., & Rabbani, S. A. (2021) · Cancers · doi:10.3390/cancers13030545 · Cited by 102
Goyal, A., Bauer, J., Hey, J., Papageorgiou, D. N., Stepanova, E., Daskalakis, M., Scheid, J., Dubbelaar, M., Klimovich, B., Schwarz, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42417-w · Cited by 102
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity
Wu, M., Kondo, H., Kammula, A. V., Shi, L., Xiao, Y., Dhiab, S., Xu, Q., Slater, C. J., Avila, O. I., Merritt, J., et al. (2024) · Science · doi:10.1126/science.adl6173 · Cited by 110
Sui, C., Zhou, Y., Shen, W.-F., Dai, B., Lu, J., Zhang, M.-F., & Yang, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1442-z · Cited by 99
Siebenkäs, C., Chiappinelli, K. B., Guzzetta, A. A., Sharma, A. R., Jeschke, J., Vatapalli, R. J., Baylin, S. B., & Ahuja, N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179501 · Cited by 100
Self-citationHuman endogenous retroviruses and their implication for immunotherapeutics of cancer
Attermann, A. S., Bjerregaard, A.-M., Saini, S. K., Grønbæk, K., & Hadrup, S. R. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy413 · Cited by 101
Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers
Saini, S. K., Ørskov, A. D., Bjerregaard, A.-M., Unnikrishnan, A., Holmberg-Thydén, S., Borch, A., Jensen, K. V., Anande, G., Bentzen, A. K., Marquard, A. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19464-8 · Cited by 115
Vitamin C – A new player in regulation of the cancer epigenome
Gillberg, L., Ørskov, A. D., Liu, M., Harsløf, L. B. S., Jones, P. A., & Grønbæk, K. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.001 · Cited by 100
Human endogenous retroviruses and cancer
María, G.-C., Paola, I., Niki, K., Mariacarmela, S., Julià, B., & Rafael, R. (2016) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0080 · Cited by 100
Lübbert, M., Grishina, O., Schmoor, C., Schlenk, R. F., Jost, E., Crysandt, M. M., Heuser, M., Thol, F. R., Salih, H. R., Schittenhelm, M. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01053 · Cited by 102
Transposon-triggered innate immune response confers cancer resistance to the blind mole rat
Zhao, Y., Oreskovic, E., Zhang, Q., Lu, Q., Gilman, A., Lin, Y. S., He, J., Zheng, Z., Lu, J. Y., Lee, J., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01027-8 · Cited by 99
Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets
Stahl, M. F., & Goldberg, A. D. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0781-7 · Cited by 102
Murayama, T., Nakayama, J., Jiang, X., Miyata, K., Morris, A. D., Cai, K. Q., Prasad, R. M., Ma, X., Efimov, A., Belani, N., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0486 · Cited by 112
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
Perrier, A., Didelot, A., Laurent‐Puig, P., Blons, H., & Garinet, S. (2020) · Biomolecules · doi:10.3390/biom10071061 · Cited by 100
Zhu, Z., McGray, A. R., Jiang, W., Lu, B., Kaliński, P., & Guo, Z. S. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01664-z · Cited by 109
Zheng, Z., Wieder, T., Mauerer, B., Schäfer, L., Kesselring, R., & Braumüller, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411673 · Cited by 113
Therapeutic targeting of DNA methylation alterations in cancer
Lee, A. V., Nestler, K. A., & Chiappinelli, K. B. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108640 · Cited by 105
Self-citationThe Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy
Yau, H. L., Ettayebi, I., & Carvalho, D. D. D. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.006 · Cited by 99
Zhang, W., Liu, W., Jia, L., Chen, D., Chang, I., Lake, M. P., Bentolila, L. A., & Wang, C. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.02.038 · Cited by 98
ADAR1: from basic mechanisms to inhibitors
Rehwinkel, J., & Mehdipour, P. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.06.006 · Cited by 99
Immunity drives TET1 regulation in cancer through NF-κB
Collignon, É., Canale, A., Wardi, C. A., Bizet, M., Calonne, E., Dedeurwaerder, S., Garaud, S., Naveaux, C., Barham, W. J., Wilson, A. J., et al. (2018) · Science Advances · doi:10.1126/sciadv.aap7309 · Cited by 96
Soldi, R., Ghosh, T., Weston, A., Thode, T. G., Drenner, K., Lewis, R., Kaadige, M. R., Srivastava, S., Ampanattu, S. D., del Villar, R. R., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235705 · Cited by 94
Epigenetic state determines the in vivo efficacy of STING agonist therapy
Falahat, R., Berglund, A., Perez-Villarroel, P., Putney, R. M., Hamaidi, I., Kim, S., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2023) · Nature Communications · doi:10.1038/s41467-023-37217-1 · Cited by 94
Griffiths, E. A., Srivastava, P., Matsuzaki, J., Brumberger, Z. L., Wang, E. S., Kocent, J., Miller, A., Roloff, G. W., Wong, H. Y., Paluch, B. E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1792 · Cited by 94
Weisenberger, D. J., Liang, G., & Lenz, H. J. (2017) · Oncogene · doi:10.1038/onc.2017.374 · Cited by 96
The Histone Code of Senescence
Paluvai, H., Giorgio, E. D., & Brancolini, C. (2020) · Cells · doi:10.3390/cells9020466 · Cited by 97
Cheu, J. W., & Wong, C. C. (2021) · Hepatology · doi:10.1002/hep.31840 · Cited by 91
Sensing of transposable elements by the antiviral innate immune system
Gázquez-Gutiérrez, A., Witteveldt, J., Heras, S. R., & Macías, S. (2021) · RNA · doi:10.1261/rna.078721.121 · Cited by 101
Qiu, Z., Zhao, L., Shen, J., Liang, Z., Wu, Q., Yang, K., Min, L., Gimple, R. C., Yang, Q., Bhargava, S., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1848 · Cited by 90
Deubiquitinase USP35 restrains STING-mediated interferon signaling in ovarian cancer
Zhang, J., Chen, Y., Chen, X., Zhang, W., Zhao, L., Weng, L., Tian, H., Wu, Z., Tan, X., Ge, X., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0588-y · Cited by 98
Wu, Y., Wu, X., Wu, L., Wang, X., & Liu, Z. (2017) · Translational research · doi:10.1016/j.trsl.2017.08.004 · Cited by 92
DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells
Yau, H. L., Bell, E., Ettayebi, I., de Almeida, F. C., Boukhaled, G. M., Shen, S. Y., Allard, D., Morancho, B., Marhon, S. A., Ishak, C. A., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.038 · Cited by 93
FOXA1 overexpression suppresses interferon signaling and immune response in cancer
He, Y., Wang, L., Wei, T., Xiao, Y., Sheng, H., Su, H., Hollern, D. P., Zhang, X., Ma, J., Wen, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147025 · Cited by 96
Varayathu, H., Sarathy, V., Thomas, B. E., Mufti, S. S., & Naik, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.559161 · Cited by 96
Cai, Y., Tsai, H.-C., Yen, R.-W. C., Zhang, Y. W., Kong, X., Wang, W., Xia, L., & Baylin, S. B. (2017) · Genome Research · doi:10.1101/gr.208108.116 · Cited by 89
Self-citationMarked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma
Chatterjee, A., Rodger, E. J., Ahn, A., Stockwell, P. A., Parry, M. F., Motwani, J., Gallagher, S. J., Shklovskaya, E., Tiffen, J. C., Eccles, M. R., et al. (2018) · iScience · doi:10.1016/j.isci.2018.05.021 · Cited by 92
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Bedognetti, D., Ceccarelli, M., Galluzzi, L., Lu, R. O., Palucka, K., Samayoa, J. A., Spranger, S., Warren, S. E., Wong, K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0602-4 · Cited by 90
Self-citationIntratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses
Jiang, X., Muthusamy, V., Fedorova, O., Kong, Y., Kim, D. J., Bosenberg, M., Pyle, A. M., & Iwasaki, A. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190801 · Cited by 91
Wood, M. A., Weeder, B. R., David, J. K., Nellore, A., & Thompson, R. F. (2020) · Genome Medicine · doi:10.1186/s13073-020-00729-2 · Cited by 94
Metadata
- Authors
- Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., Makarov, V., Buhu, S., Slamon, D. J., Wolchok, J. D., Pardoll, D. M., Beckmann, M. W., Zahnow, C. A., Merghoub, T., Chan, T. A., Baylin, S. B., & Strick, R.
- Affiliations
- Johns Hopkins University (US)
- Universitätsklinikum Erlangen (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Case Western Reserve University (US)
- University of California, Los Angeles (US)
- Corresponding author
- Baylin, Stephen B.
- Strick, Reiner
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 162
- Issue
- 5
- Pages
- 974-986
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4556003
- OpenAlex
- W1953890763
- Cited by
- 2,022
- References
- 94
- Citations by year
- 2026: 193 · 2025: 188 · 2024: 211 · 2023: 209 · 2022: 225 · 2021: 250 · 2020: 184 · 2019: 163 · 2018: 161 · 2017: 133 · 2016: 93 · 2015: 10
- FWCI
- 65.10
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA058184, CA058184, F32CA183214, P30CA008748)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- hypomethylating agents, DNA methylation, type I interferon response, double-stranded RNA sensing, endogenous retroviruses, ovarian cancer, melanoma, TLR3, MAVS, interferon-beta, apoptosis, immune checkpoint therapy, CTLA-4, tumor immune microenvironment, epigenetic reprogramming
- MeSH terms
- Animals, Azacitidine, Female, Humans, Immunotherapy, Interferon Type I, Lung Neoplasms, Melanoma, Mice, Inbred C57BL, Ovarian Neoplasms, RNA, Double-Stranded, DNA Modification Methylases, DNA Methylation, Endogenous Retroviruses, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
